Table 2 Ethylclucuronide (EtG) quantitative findings, smoking status and cannabis use in the study population
Clinic | Samples | EtG Negative | EtG 100-300 ng/mL | EtG > 300 ng/mL | cotinine + /EtG negative | cotinine + / EtG 100-300 ng/mL | cotinine + / EtG > 300 ng/mL | cannabis + /EtG negative | cannabis + / EtG > 100 ng/mL |
|---|---|---|---|---|---|---|---|---|---|
HAL, antenatal clinic for women with problematic substance use | 68 | 82.4% (56/68) | 10.3% (7/68) | 7.4% (5/68) | 22.6% (12/53) | 71.4% (5/7) | 100% (5/5) | 3.8% (2/53) | 17% (2/12) |
LCH, Lahti central hospital antenatal clinic | 212 | 92.5% (196/212) | 5.7% (12/212) | 1.9% (4/212) | 25.9% (7/27) | 25% (3/12) | 50% (2/4) | 7.4% (2/27) | 0% (0/16) |
USR, Helsinki, a community maternity clinic | 58 | 93.1% (54/58) | 6.9% (4/58) | 0% (0/58) | 5.6% (1/18) | 0% (0/4) | 0% (0/0) | 0% (0/18) | 0% (0/4) |
USR, Lahti, a community maternity clinic | 50 | 92% (46/50) | 6% (3/50) | 2% (1/50) | 10% (1/10) | 0% (0/3) | 100% (1/1) | 0% (0/10) | 0% (0/4) |
USR, Helsinki Prenatal ultrasound screening unit | 117 | 94% (110/117) | 5.1% (6/117) | 0.8% (1/117) | 0% (0/31) | 0% (0/6) | 0% (0/1) | 0% (0/31) | 0% (0/7) |
All | 505 | 91.5% (462/505) | 6.3% (32/505) | 2.2% (11/505) | 15.1% (21/139) | 25% (8/32) | 72.7% (8/11) | 2.9% (4/139) | 6.3% (2/32) |
All except HAL | 437 | 92.9% (406/437) | 5.7% (25/437) | 1.4% (6/437) | 10.5% (9/86) | 12% (3/25) | 50% (3/6) | 2.3% (2/86) | 0% (0/25) |